Financial Data Summary - The company reported a preliminary net loss attributable to the parent company of approximately -79,798.56 million RMB, a decrease in loss of about 37.70% compared to the previous year [5] - The net loss attributable to the parent company, excluding non-recurring gains and losses, is expected to be around -91,246.08 million RMB, reflecting a decrease in loss of approximately 29.26% year-on-year [5] Business Performance and Financial Condition - The core product, Toripalimab injection (brand name: Tuoyi), saw a significant sales revenue increase of approximately 37.72% year-on-year in the domestic market [2] - As of the announcement date, Tuoyi has been included in the national medical insurance catalog for all 12 approved indications, making it the only anti-PD-1 monoclonal antibody for treating renal cancer, triple-negative breast cancer, and melanoma in the catalog [2] - The company is expanding its global commercialization network, with Toripalimab approved for sale in over 40 countries and regions, including mainland China, Hong Kong, the United States, the EU, India, the UK, Australia, and Singapore [2] Operational Strategy - The company is implementing a "quality improvement and efficiency enhancement" action plan, which has led to a significant narrowing of net losses compared to the previous year while maintaining efficient progress on its core pipeline [3] - The company is advancing several innovative drugs with international market competitiveness, including JS207 (a PD-1/VEGF dual antibody), JS212 (an EGFR/HER3 ADC), and JS213 (a PD-1/IL-2 fusion protein), with ongoing clinical trials exploring various combination therapies [3][4] - The company is focused on cost control and resource allocation while maintaining high efficiency in its core pipeline, which has contributed to a reduction in losses [4]

Core Viewpoint - The company reported a significant reduction in net losses for the fiscal year 2025, driven by increased sales of its core product, Toripalimab injection (brand name: Tuoyi R), and effective cost management strategies [1][2][3]. Financial Data and Indicators - The estimated net loss attributable to the parent company for 2025 is approximately RMB 797.99 million, a decrease of about RMB 482.94 million or 37.70% compared to the previous year [1][5]. - The estimated net loss after excluding non-recurring gains and losses is approximately RMB 912.46 million, a decrease of about RMB 377.43 million or 29.26% year-on-year [1][5]. Business Performance and Financial Condition - Sales revenue from Toripalimab injection increased significantly by approximately 37.72% year-on-year, with all 12 approved indications included in the national medical insurance catalog [2][3]. - The company has expanded its global commercialization network, with Toripalimab approved in over 40 countries and regions, including mainland China, Hong Kong, the United States, and the European Union [2][3]. Operational Strategies - The company implemented a "quality improvement and efficiency enhancement" action plan, which led to a notable reduction in net losses while maintaining a focus on core pipeline advancements [3][5]. - The company is advancing multiple innovative drugs in clinical trials, including JS207, JS212, and JS213, and is exploring various combination therapies to maximize pipeline synergy [3][5].

Core Viewpoint - The company, Junshi Biosciences, forecasts a significant increase in revenue for the year 2025, alongside a reduction in net losses compared to the previous year [2][9]. Financial Performance Forecast - The company expects to achieve approximately 2.5 billion yuan in revenue for 2025, representing a year-on-year increase of about 28.32% [2]. - Research and development expenses are projected to be around 1.353 billion yuan, reflecting a growth of approximately 6.10% compared to the previous year [2]. - The net loss attributable to the parent company is anticipated to be around 873 million yuan, a reduction of approximately 31.85% year-on-year [2][3]. - After excluding the impact of share-based payments, the net loss is expected to be around 799 million yuan, indicating a decrease of about 37.62% compared to the previous year [2][3]. Previous Year Performance - In 2024, the company reported a revenue of approximately 1.949 billion yuan [5]. - The R&D expenses for 2024 were about 1.275 billion yuan [6]. - The total profit for 2024 was a loss of approximately 1.358 billion yuan, with a net loss attributable to the parent company of around 1.281 billion yuan [6]. Reasons for Performance Changes - The increase in revenue is primarily attributed to the growth in sales of commercialized drugs, particularly the core product, Toripalimab injection (brand name: Tuoyi), which saw significant sales growth in the domestic market [8][9]. - The company has expanded its global commercialization network, with Toripalimab approved for sale in over 40 countries and regions, enhancing its competitive edge [8][9]. - Despite the expected net loss, the company has improved its commercial capabilities and cost management, focusing on high-efficiency advancement of its core pipeline, including several innovative drugs in clinical trials [9].